Victoria Socha

DocwireNews

Immunoglobulin A nephrology (IgAN) is the most common biopsy-proven glomerular disease. Patients who develop IgAN following kidney transplantation commonly experience allograft loss. Previous studies have demonstrated an association between corticosteroid maintenance and a lower risk of recurrent glomerulonephritis, including IgAN. However, there are no differences in patient survival or death censored graft survival between use of steroids and no steroid use.The Scripps Center for Organ and Cell Transplantation, La Jolla, California, utilizes a rapid corticosteroid withdrawal (CSW) protocol (d. 0-2 only) that is substantially lower than that at most transplant centers. Clinicians at the center, led by S. Kurian, conducted an analysis to compare clinical outcomes of transplant recipients with IgAN in the CSW program with results as reported in publicly available United Network for Organ Sharing (UNOS) data. Analysis results were presented during a <a href="https://atcmeetingabstracts.com/abstract/iga-nephropathy-outcomes-after-kidney-transplantation-in-an-early-corticosteroid-withdrawal-center/">poster</a> session at the virtual American Transplant Congress 2020 in a poster titled IgA Nephropathy Outcomes after Kidney Transplantation in an Early Corticosteroid Withdrawal Center.The analysis included all living and deceased donor renal transplant recipients at the center or from the UNOS transplant database from January 1, 1999, to December 31, 2018. Exclusion criteria were &lt;18 years of age, liver-kidney transplantation, primary non-function, patients with retransplants, or loss to follow-up.A total of 61 patients with IgAN native kidney disease from the Scripps Center were used for the analysis. Following application of the same exclusion criteria to the UNOS data and limiting of the UNOS cohort to patients on FK [tacrolimus] and mycophenolate mofetil maintenance, a total of 1991 patients with IgAN met the analysis criteria and were indicated as steroid free at discharge and no corticosteroid use indicated at any follow-up. The statistical comparisons of proportions utilized a 2-sample chi-squared test for equality of proportions with Yate&rsquo;s continuity correction.All-cause graft failures in patients with IgAN were not significantly different at the Scripps Center when compared with the UNOS Data (6.6% vs 5.1%, respectively; P&lt;.80). In a comparison of all-cause mortality between the center and the UNOS data, there were no significant differences in IgAN mortality rates (8.2% vs 3.7%, respectively; P&lt;.10).In conclusion, the researchers said, &ldquo;These preliminary findings indicate that patients at our center who are early corticosteroid withdrawal following <a href="https://www.docwirenews.com/nephtimes/nephtimes-diseases-and-conditions/diabetes-hypertension/risk-factors-for-new-onset-diabetes-following-kidney-transplantation/">transplant</a> with IgAN as primary diagnosis have comparable outcomes in terms of all-cause graft failure and mortality with patients listed in UNOS. A limitation of the present study is that given the low incidence rates, we would require a larger cohort of patients to study at our center in order to make definitive statistical conclusions. However, these preliminary findings assure us that IgAN outcomes are not a cause of concern in our early corticosteroid withdrawal center.&rdquo;Source: Kurian S, Spierling S, Barrick B, Rice J, Case J, Marsh C. IgA nephropathy outcomes after kidney transplantation in an early corticosteroid withdrawal center. Abstract of a poster presented at the virtual American Transplant Congress 2020 (Abstract D-051), May 30, 2020.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Early Corticosteroid Withdrawal and Outcomes in IgAN after Transplantation

American Transplant Congress 2020

Immunoglobulin A nephrology (IgAN) is the most common biopsy-proven glomerular disease. Patients who develop IgAN following kidney transplantation commonly experience ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe